Wedbush restated their outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Get Rating) in a research note released on Monday, Benzinga reports. They currently have a $23.00 price target on the stock. Several other equities research analysts also recently commented on VIGL. Morgan Stanley upped their price objective on shares of Vigil Neuroscience from […]
Mizuho assumed coverage on shares of Vigil Neuroscience (NASDAQ:VIGL – Get Rating) in a research note released on Thursday morning, The Fly reports. The brokerage issued a buy rating and a $15.00 price objective on the stock. Other research analysts also recently issued reports about the company. Morgan Stanley upped their price objective on Vigil […]
Mizuho assumed coverage on shares of Vigil Neuroscience (NASDAQ:VIGL – Get Rating) in a research note released on Thursday morning, The Fly reports. The brokerage issued a buy rating and a $15.00 price objective on the stock. Other research analysts also recently issued reports about the company. Morgan Stanley upped their price objective on Vigil […]
Vigil Neuroscience (NASDAQ:VIGL – Get Rating) had its price target upped by Morgan Stanley from $12.00 to $13.00 in a report released on Monday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock. Separately, HC Wainwright restated a buy rating and set a $24.00 price objective on shares of Vigil […]
Company remains on track to report interim data from Phase 2 trial in the second half of 2023WATERTOWN, Mass., March 30, 2023 Vigil Neuroscience, Inc. , a clinical-stage biotechnology. | March 30, 2023